Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis

• Published in: Frontiers in pharmacology Vol. 15; p. 1393861
• Main Authors: Peng, Jian-Xin, Wang, Ling-Zhi, Wang, Qiu-Ting, Li, Hui-Long, Lin, Li-Jun, He, Jun-Ming
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.08.2024
• Subjects: entecavir; hepatitis B; hepatocellular carcinoma; overall survival rates; Pharmacology; recurrence-free survival rate; tenofovir; hepatitis B; tenofovir; recurrence-free survival rate; overall survival rates; meta-analysis; entecavir; hepatocellular carcinoma
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2024.1393861

Hepatitis B, often leading to Hepatocellular carcinoma (HCC), poses a major global health challenge. While Tenofovir (TDF) and Entecavir (ETV) are potent treatments, their comparative effectiveness in improving recurrence-free survival (RFS) and overall survival (OS) rates in HBV-related HCC is not well-established. We conducted an individual patient data meta-analysis using survival data from randomized trials and high-quality propensity score-matched studies to compare the impact of Tenofovir (TDF) and Entecavir (ETV) on RFS and OS in HBV-related HCC patients. Data from six databases and gray literature up to 30 August 2023, were analyzed, utilizing Kaplan-Meier curves, stratified Cox models, and shared frailty models for survival rate assessment and to address between-study heterogeneity. The study employed restricted mean survival time analysis to evaluate differences in RFS and OS between TDF-treated and ETV-treated patients. Additionally, landmark analyses compared early (<2 years) and late (≥2 years) tumor recurrence in these cohorts. This study incorporated seven research articles, covering 4,602 patients with HBV-related HCC (2,082 on TDF and 2,520 on ETV). Within the overall cohort, TDF recipients demonstrated significantly higher RFS ( = 0.042) and OS ( < 0.001) than those on ETV. The stratified Cox model revealed significantly improved OS for the TDF group compared to the ETV group (hazard ratio, 0.756; 95% confidence interval, 0.639-0.896; = 0.001), a result corroborated by the shared frailty model. Over a follow-up period of 1-8 years, no significant difference was noted in the mean time to death between the TDF and ETV groups. The rates of early recurrence did not significantly differ between the groups ( = 0.735). However, TDF treatment was significantly associated with a reduced risk of late recurrence compared to ETV ( < 0.001). In the HCC resection subgroup, the disparities in OS, early, and late recurrence rates between the two treatments paralleled those seen in the overall cohort. Compared to ETV, TDF may enhance OS and reduce late tumor recurrence risk in HBV-related HCC patients receiving curative treatment. However, there was no statistically significant distinction in the timing of tumor recurrence and mortality between patients administered TDF and those prescribed ETV. http://www.crd.york.ac.uk/prospero/.